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Summary
Immunoglobulin G-binding factors (IgG-BF), which are produced by cells of the immune sys-
tem, inhibit antibody production. In this paper, we show that transforming growth factor-(3
(TGF-(3) suppresses secondary in vitro anti-sheep red blood cell responses of mouse spleno-
cytes and lipopolysaccharide- or anti-IgM--stimulated mouse B cell responses in a way similar
to, and with the same kinetics as, rodent IgG-BF. Moreover, the immunosuppressive activity
ofIgG-BF was totally neutralized by polyclonal and monoclonal anti-TGF-(3 antibodies and it
eluted with TGF-(3 by gel exclusion chromatography, suggesting that a TGF-R-like immuno-
suppressive factor is present in IgG-BF. We also show that TGF-R behaves as an IgG-BF since
it binds to insolubilized IgG, but not to insolubilized F(ab')2 or bovine serum albumin. Alto-
gether, the data support the concept of a biological role for TGF-(3 in the IgG-mediated nega-
tive feedback of antibody responses.
Antibody production is the consequence of antigen- A I B cell activation, proliferation, and differen-
tiation into plasma cells. Each step of this complex process
is closely regulated by enhancing or inhibiting factors. Cy-
tokines such as IL-4, IL-2, or IL-5 drive B cells through
the cell cycle, and IFN-y, TGF-(3, or IL-4 modulate the
isotypic profile of the antibody responses (1, 2) . Among the
regulatory loops involved in antibody production, a nega-
tive feedback is exerted by IgG antibodies. It requires the
Fc portion of the IgG and decreases the production of all Ig
isotypes. Two nonexclusive mechanisms have been pro-
posed for this activity. First, the cross-linking of the B cell
receptor to receptors for the Fc portion of IgG (FcyR)' at
the cell membrane, via IgG antibodies reacting both with B
cell receptor and with FcyR, induces a negative signal in B
cells by inhibiting the early events of activation (3-5) . Sec-
ond, the interaction of IgG immune complexes with FcyR
positive cells induces the production of suppressor factors
(6). Among these factors, IgG-binding factors (IgG-BF) (7)
have been shown to inhibit both IgM and IgG antibody
production (8-13) .
The origin and nature of IgG-BF have been extensively
investigated. IgG-BF are produced by activated T and B
lymphocytes, NK cells, macrophages, and cells of my-
elomonocytic origin (7-9, 12-14) . Since these cells express
'Abbreviations used in this paper: ATC, alloantigen-activated T cells; BHK,
baby hamster kidney; F(ab')z, fragments of pepsin-cleaved IgG; FcyR, re-
ceptors for the Fc portion of IgG; IgG-BF, IgG-binding factor; LAP, la-
tency-associated peptide; PFC, plaque-forming cells; sFcyR, soluble re-
ceptors for IgG.
FcyR and since IgG increases FcyR expression and IgG-
BF production (9, 14), the soluble forms of FcyR (sFcyR)
were thought to be likely candidates for suppressor IgG-BF.
Three types ofFcyR have been identified (15) : FcyRI is
a high affinity receptor for monomeric IgG, while FcyRII
and FcyRIII are low affinity receptors that bind IgG im-
mune complexes. In mice, the ectodomains of FcyRII and
FcyRIII exhibit 95% sequence homology. Soluble forms of
FcyR are generated either by splicing of the exon encod-
ing the transmembrane region of FcyRII (16) or by pro-
teolytic cleavage of the extracellular part of the membrane
FcyRII (17) or FcyRIII (18) . To establish whether sFcyR
are at least partially responsible for the suppressive activity
of IgG-BF, a recombinant murine sFcyR corresponding to
the FcyRII ectodomain, and thus highly homologous to
membrane-cleaved FcyRII and FcyRIII, was produced by
transfection of eukaryotic cell lines with a mutant comple-
mentary DNA containing a stop codon (19). This sFcyR
was purified up to 98% homogeneity by a succession of
chromatography steps, including affinity chromatography
on insolubilized IgG (19, 20). The resulting preparations
inhibited IgM and IgG antibody production to SRBC both
in vitro (18-21) and in vivo (18, 21).
Cells of the immune system produce endogenous immu-
noregulatory molecules such as TGF-(3. TGF-(3 belongs to
a superfamily of structurally related proteins and is pro-
duced by a variety of cells, including fibroblasts, activated
lymphocytes, macrophages, and platelets (22). The three
mammalian isoforms of TGF-(3 (TGF-Rl, -(32, and -R3)
share 70-80% amino acid sequence identity and each iso-
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described activity as transforming factor, TGF-P exerts
pleiotropic activities, regulating many immune and inflam-
matory processes such as cell proliferation (22, 23), anti-
body production (24, 25), and cytotoxic T (26) and LAK
cell generation (27, 28). TGF-P is synthesized and secreted
as a latent molecule that does not bind to the TGF-P re-
ceptors. Various conditions, such as acid or alkaline treat-
ment, heating at 100°C, as well as proteases and glycosi-
dases, can activate latent TGF-P into a biologically active
molecule (29) . An intriguing property of TGF-P family
members is that, in addition to their cellular receptors, they
bind to several proteins such as latency-associated peptide
(30), ct2-macrocroglobulin (31), cx-fetoprotein (32), fibro-
nectin (33), sulphate proteoglycan decorin (34), and man-
nose 6-phosphate receptor (35) .
Since cells that are used to produce sFcyR also produce
TGF-(3, and since TGF-P has a high anti-proliferatioe ac-
tivity, the present study was conducted to provide a better
understanding of the respective roles ofTGF-P and sFcyR
in the suppressive activity of IgG-BF. Soluble FcyR se-
creted by transfected cell lines and by mouse activated T
cells was used as the source of IgG-BF. First, we showed
that TGF-P was present, together with sFcyR, in affinity-
purified IgG-BF. Second, we observed that IgG-BF and
purified porcine TGF-P inhibit B cell proliferation and an-
tibody production with identical kinetics. Third, we dem-
onstrated that neutralizing antibodies to TGF-P abolished
the suppressive activity ofIgG-BF and that the active factor
eluted with TGF-P by gel exclusion chromatography, and
not with sFcyR. Finally, we showed that purified TGF-P
binds to IgG-Sepharose, and not to F(ab')z- or BSA-
Sepharose, thus behaving as an IgG-BF. This property sug-
gests a biological role for TGF-(3, together with IgG anti-
bodies, in the IgG-mediated negative feedback ofantibody
responses.
Materials and Methods
Mice.
￿
8-10-wk-old (C57BL/6J X DBA/2J)F1 (B6D2)F1 male
mice were used for the preparation of resting B cells. 4-wk-old
C3H mice were used as donors ofthymus cells andDBA/2 mice,
8-wk-old, were used as recipients forthepreparation ofalloantigen-
activated T cells. All mice were obtained from IFFA CREDO
(L'arbresle, France).
Antibodies and Growth Factors.
￿
The rat hybridoma cell line
J1j.10-producing IgM anti-mouse Thy-1 mAb was obtained from
the American Type Culture Collection (Rockville, MD). The rat
anti-mouse FcyRII/III mAb 2AG2 (36) was purified by chroma-
tography on protein G. The neutralizing polyclonal chicken IgY
anti-porcine or anti-human TGF-(31 and control IgY were pur-
chased from R & D Systems, Inc. (Minneapolis, MN). Mono-
clonal mouse IgG, anti-TGF-(31, -R2, and-(33 (generated against
bovine TGF-(32) was obtained from Genzyme (Cambridge,
MA). Mouse IgG2a and IgGI were purified by chromatography
on protein A-Sepharose of culture supernatant of the IgG2a anti-
SRBC and IgGI secreting hybridomaline UN2C3 and U182, re-
spectively (19) . F(ab')2 fragments of rabbit IgG (Nordic, Tilburg,
The Netherlands) were obtained by pepsin digestion (2% wt/wt)
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followed by protein A-Sepharose chromatography. The IgG and
F(ab')2 fragments were pure as determined by Coomassie blue
staining afterSDS-PAGE. They were coupled to activated Sepha-
rose 413 (7 mg protein/ml Sepharose) according to the manufac-
turer's recommendations (Pharmacia, St. Quentin en Yvelines,
France) . To obtain polyclonal anti-IgG-BF antibodies, rabbits
were hyperimmunized by a footpad injection of 100 N.g of IgG-
BF isolated as describedbelowin CFA, followed by three succes-
sive boostings by intraperitoneal injections at 2-wk intervals.
Goat affinity-purified F(ab')2 fragments to murine IgM were pur-
chased from Organon Teknica Corp. (Durham, NC). TGF-R1
purified from porcine platelets was purchased from R & D Sys-
tems. Before use, the lyophilized preparations were dissolved in 4
mM HCl containing 1 mg/ml BSA. In some experiments, 1 ml
porcine TGF-(31 (200 ng) in 20 mM Tris buffer, pH 7.6, was in-
cubated with 0.1 ml Sepharose-coupled rabbit IgG or F(ab')2
fragments of rabbit IgG for 18 h at 4°C. After five washes in the
same buffer, bound material was eluted in 0.3 ml 0.2 M glycine
HCl buffer, pH 2.8, neutralized and dialyzed against PBS before
use. LPS from Escherichia coli was purchased from Sigma Immu-
nochemicals (St. Louis, MO).
Purification ofIgG-BF Produced by Transfected Cell Lines.
￿
Fibro-
blastic mouse L and baby hamster kidney (BHK) cell lines were
transfected with pKC3 plasmid containing a cDNA encoding the
174-NH2-terminal amino acids ofmouse FcyRII (19, 20). Three
cell lines, Cu1B3 derivedfrom L cells, and IVC2 and 6/9CII de-
rived from BHK cells, were obtained. To scale up production,
these transfected cell lines were grown on hollow fibers in a per-
fusion cell culture system (Acusyst Jr.; Endotronics Inc., Coon Rap-
ids, MN). As estimated by ELISA, CulB3, IVC2, and6/9CII cell
lines produced 1, 5.6, and 5.2 mg/d sFcyR, respectively (20).
Recombinant sFcyF was purified from culture medium by ion
exchange chromatography followed by affinity chromatography.
The culture medium (150 ml) was equilibrated in 20 mM Tris
buffer, pH 7.6. All equilibrations steps were performed by Sepha-
dex G25 (Pharmacia) chromatography. The material was then ap-
plied on a column containing 10 ml S-Sepharose (Fast Flow;
Pharmacia). After washes with the same buffer, proteins were
eluted with 20 mM Tris buffer, pH 7.6, containing 0.5 M NaCl.
After equilibration in 20 mM Tris buffer, pH 7.6, the material
from BHK andL transfected cell lines was applied to 1 ml of rab-
bit IgG- or mouse IgG2,-coupled Sepharose, respectively. The
column was washed with equilibration buffer and the proteins
were eluted with 0.1 M sodium acetate buffer, pH 4. The eluted
material was equilibrated in PBS, spun for 15 min at 9000 g, ster-
ilized by UV irradiation, and stored at -80°C in aliquots. These
procedures led to the isolation ofIgG-BF containing 98% recom-
binant sFcyR with a 30% yield (20). Deglycosylation of 20 N,g
purified material was performed by incubation with 200 U N-gly-
cosidase F (Biolabs, Beverly, MA). For gel exclusion chromatog-
raphy, 0.25 n11 ofIgG-BF was applied at 0.5 ml/min on a Superdex
75 HR10/30 column (Pharmacia) equilibrated in PBS. Fractions
(0.5-ml) were collected andtested for biological activity andTGF-P
and sFcyR contents.
Purification ofIgG-BFfrom Supernatants ofAlloantigen-activated T
Cells (ATC). ATC were obtained as previously described (6).
Briefly, 10$ thymocytes from C3H mice were injected in the tail
vein of 850-rid irradiated DBA/2 recipients. 5 dlater, spleen cells
(95% Thy-1+) were harvested and incubated for 2 h at 37°C in
HBSS (GIBCO BRL, Paisley, Scotland). Supernatants were col-
lected and spun at 1800 g. IgG-BF was purified by affinity chro-
matography on rabbit IgG as described (7, 8).
B Cell Responses.
￿
Spleen cell suspensions were depleted of T
Transforming Growth Factor (3 in Immunoglobulin G-binding Factorcells by treatment with crude supernatant ofjlj.10 cell line for 30
nun at room temperature in HBSS (Gibco) followed by two suc-
cessive 15-nun incubations at 37°C with the appropriate dilution
(previously determined) of rabbit C (serum from 3-wk-old rab-
bit) . Resting B cells were isolated by Percoll (Pharmacia) density
centrifugation as previously described (24). The cellsbandingbe-
tween 70 and 60% Percoll were collected and washed twice with
HBSS. These cells, representing the source ofresting B lympho-
cytes, were 95% IgM+ and did not proliferate significantly in cul-
tures performed in the presence of 2 wg/ml Con A (Sigma; data
not shown). Resting B cells (5 X 10^) were cultured (in dupli-
cate) in 0.2 ml of RPMI 1640 culture medium (GIBCO) supple-
mented with 2 MM L-glutamine (GIBCO), 100 U/ml of penicil-
lin and 100 p,g/ml of streptomycin (GIBCO), 5 X 10-s M
(3-mercaptoethanol (GIBCO), and 10% heat-inactivated FCS
(Seromed, Berlin, Germany), containing 50 "/ml of LPS or 15
N.g/ml of F(ab')Z anti-IgM at 37°C, in an atmosphere containing
5% COZ in 96-well microplates (Becton Dickinson, Grenoble,
France). 48 and 66 h after the onset of anti-IgM stimulation and
LPS stimulation, respectively, proliferation was assayed by pulsing
the cells with 0.5 p,Ci perwell of [3H]thymidine (Amersham, Les
Ulis, France) for the last 18 h of culture. Cells were then har-
vested with a 96-well harvester (Skatron Instruments, Norway),
and collected on a glass fiber filter (Pharmacia). The radioactivity
was counted in a Betaplate (Pharmacia LKB) . 7 d after initiation
of the cultures stimulated by LPS, the supernatants were collected
by centrifugation and tested for their Ig content.
ELISA.
￿
The amounts of Igs were determined by an isotype-
specific ELISA (24) using 96-wellflat-bottom immunoplates (DK
4000; Nunc, Roskilde, Denmark) coated with goat antibodies di-
rected against mouse IgM or IgG (Southern Biotechnology As-
sociates, Birmingham, AL) and alkaline phosphatase-labeled goat
anti-mouse IgM or IgG3 antibodies (Southern Biotechnology) for
detection. Ig concentrations were calculated from the absorbance
units by extrapolation from standard curves determined with pu-
rified mouse antibodies (Southern Biotechnology). Titration of
sFcyR was performed as previously described (20). Briefly, 96-
well flat-bottom immunoplates (Nunc) were coated with 2.4G2
mAb, washed, and saturated. 50 N,l of serial twofold dilutions of
sFcyR-containing samples or 98% pure recombinant sFcyR used
as a standard were added and incubated for 2 h at 20°C. Plates
were then incubated with rabbit IgG anti-IgG-BF (10 wg/ml).
After washes, goat anti-rabbit IgG coupled to alkaline phos-
phatase (Southern Biotechnology) was added for the detection.
Optical densities were measured at 405 nm with an ELISA reader
(Titertek Multiskan; Labsystems France, Les Ulis, France) con-
nected to an Olivetti M240 computer. The sensitivity of this
ELISA is 25 ng/ml. An ELISA for TGF-(3 hasbeen developed in
our laboratory. The 96-well flat-bottom immunoplates (Nunc)
were coated overnight at 4°C with mouse monoclonal anti-
TGF-R diluted (5 l.tg/ml) in 0.05 MNa1C03/NaHCO3, pH 9.6.
After washes and saturation with 0.05% PBS, Tween 20 (Merck,
Schuchardt, Germany), and 2% BSA (Sigma) for 1 h at 37°C, 50
wl of serial twofold dilutions in 0.05% PBS, Tween 20, and 2%
BSA of samples acidified as described (27) were incubated for 1 h
at 37°C. After washes, chicken IgY anti-human TGF-(31 anti-
bodies diluted (1 :500) in PBS 0.05%, Tween 20, and 2% BSA
were added andincubated overnight at 4°C. For detection, plates
were first incubated with goat anti-chicken IgY coupled to alka-
line phosphatase (SouthernBiotechnology), 1 :10,000, 3 hand 30
min at 20°C, and then with the substrate (p-nitrophenyl phos-
phate; GIBCO). After 15 min, the amplifier was added (GIBCO)
and optical densities were measured at 492 nm. Human rTGF-(31
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was used as a standard (R & D Systems) . This ELISA detects con-
centrations of human TGF-R1 that are >1 ng/ml. Its reactivity
for TGF-(32 and -(33 is unknown at the present time.
Secondary In Vitro Antibody Responses.
￿
Spleen cells (6 X 106)
from B6D2 mice primed in vivo with SRBC were cultured in 1 ml
RPMI, 10% FCS, and 1% horse serum for 5 d with SRBC as de-
scribed (37) . Indirect IgG plaque-forming cells (PFC) were enu-
merated by an indirect hemolytic plaque assay in liquid medium
using rabbit anti-mouse IgG antiserum and guinea pig serum as a
source of complement. Products or PBS, used as a positive con-
trol, were added on day 0 in a final volume of0.1 ml. Results are
expressed as the number of indirect PFC per 106 recovered cells.
SDS-PAGE and Western Blotting.
￿
One-dimensional
￿
discon-
tinuous SDS-PAGE was carried out on 10 or 12.5% polyacryl-
amide gels. Before layering onto the gel, proteins were boiled for
3 min in 50 mM Tris-HCl, pH 6.8, 1% SDS, 10% glycerol, and
0.001% bromophenol blue. For reducing conditions, 0.7 M R-2
mercaptoethanol (Sigma) was added. For Western blotting, non-
reduced samples were run on 12.5% acrylamide SDS minigels and
transferred to nitrocellulose filters (Schleicher & Schnell, Darsel,
Germany) using a semi-dry transfer apparatus (Bio Rad Laborato-
ries, Hercules, CA). Electroblotting wasperformedat 22 V using
25 mM Tris, 192 mM glycine, and 20% ethanol as transfer buffer.
The nitrocellulose membranes were saturated for 1 h at 37°C in
TBS (10 mM Tris, 150 mM NaCl, pH 7.4) containing 5% BSA
(Sigma). Primary antibodies (chicken anti-porcine TGF-(31 or rab-
bit anti-IgG-BF) diluted in TBS with 5% BSA (wt/vol) (3 FLg/ml
for anti-TGF-(31, 1:1,000 for anti-IgG-BF) were incubated with
the blocked nitrocellulose membranes overnight at 4°C. Excess
antibody was removed with three 10-min washes in TBS. The ni-
trocellulose filters were then incubated with secondary antibodies
coupled to alkaline phosphatase (Southern Biotechnology) di-
luted to 1 :1,000 in TBS with 5% BSA (wt/vol) for 1 h at room
temperature. After five 10-min washes in TBS, filters were re-
vealed using the BCIP/NBT Phosphatase Substrate System
(Kirkegaard & Perry Laboratories, Gaithersburg, MD).
Results
Soluble FcyR and TGF-P Are Present in IgG-BF.
￿
Culture
medium of the Cu1B3 cell line transfected with a cDNA
encoding sFcyR was subjected to ion exchange chroma-
tography and affinity chromatography on Sepharose-coupled
IgG. The suppressive activity of the preparations was as-
sessed in three separate experiments, by inhibition of a sec-
ondary in vitro anti-SR-BC response, evaluated by count-
ing the indirect IgG-PFC. The starting material and the
affinity-purified preparation, i.e., IgG-BF, inhibited anti-
body production to SR-BC. A >10 fold-enrichment in
specific activity was achieved by the purification process,
since 50% inhibition was obtained with 2.75 l.Lg/ml of af-
finity-purified IgG-BF as opposed to 30 NLg/ml of starting
material (Fig. 1 A).
SDS-PAGE analysis of the proteins present in starting
material and in IgG-BF purified from supernatants of Cu-1133
cell line revealed enrichment for a group of proteins rang-
ing from 30 to 45 kD (Fig. 1 B) . Quantification by ELISA
showed that this enrichment was 300-fold. As previously
observed (16, 17), these proteins gave a single band corre-
sponding to the 20-kD polypeptide ofsFcyR after deglyco-
sylation (data not shown) . When the preparation was ana-lyzed by Western blotting using an antiserum to IgG-BF, a
major band corresponding to sFcyR (30-45 kD) was visi-
ble (Fig. 1 C) . When analyzed using anti-TGF-R antibodies,
one band corresponding to a 25 kD-polypeptide was visible
in addition to slower migrating ones (Fig. 1 D) . As estimated
by Western blotting by comparison with different doses of
standard porcine TGF-R, 0.5 ng 25 kD TGF-(3 was de-
tected in 30 NLg of purified IgG-BF. Similar results were
found with another IgG-BF preparation from the same cell
line (data not shown) . As illustrated in Fig . 1 D, 25 kD
TGF-R was also detected by Western blotting in IgG-BF
purified from the culture media of other cell lines secreting
recombinant sFcyR, such as 6/9CII (four preparations) and
IVC2 (five preparations) . In IgG-BF from the IVC2 cell
line, anti-TGF-R antibodies revealed additional slower mi-
grating proteins (Fig . 1 D) .
0.5
1 .5
1s
so
[3H] thymidine incorporation
soon 10900 15900 20900 25990
F/M%/MEN%~N01
%%%%%/
ii iii,
Vol
9.90005
9 .9995
9.905
0.s
[3H] thymidine incorporation
5ooo 10000 15900 20000 _ zsooo
Activated T cells secrete soluble FcyR (7, 38) as well as
TGF-R (38) . IgG-BF was purified from culture superna-
tants ofmouse ATC and analyzed similarly. As shown in
Fig. 1 D, the T cell-produced IgG-BF contained 25 kD
TGF-R in addition to slower migrating TGF-R-reactive
components including a prominent protein doublet .
Comparative Inhibitions of IgG-BF and TGF-/3 on B Cell
Responses . Antibody production to SRBC is a complex
process that involves different cell types. To more clearly
define the experimental model, we used purified mouse
resting splenic B cells directly stimulated either by anti-IgM
F(ab')2 antibodies (15 pg/ml) or by LPS (50 [Lg/ml) . Anti-
IgM stimulation triggered B cell proliferation but not Ig
production (Fig . 2), whereas LPS activation drove B cells
through proliferation to IgM and IgG3 production (Fig. 3) .
On day 0, IgG-BF or porcine TGF-R1 was added to cell
C
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￿
Soluble FcyR and TGF-(3
are present in different IgG-BF . (A)
Inhibition of secondary in vitro anti-
SRBC response by starting material
(S. Mat) and IgG-BF from Cu1B3 cell
line. Products were added on day 0,
and the response was measured on day
5. Results are expressed as the number
ofindirect PFC per 106recovered cells
(means ± SEM of duplicate values) .
(B) Analysis of S . Mat . and IgG-BF
from the CulB3 cell line by SDS-
PAGE followed by silver staining (5
N,g per sample) . (C) Analysis of IgG-
BF (25 Icg) from Cu1B3 cell line by
Western blotting with rabbit anti-
IgG-BF antiserum (1 :1,000) . (D)
Analysis ofporcine TGF-131 (5, 1, and
0.2 ng), S . Mat . (25 Wg) from the
Cu1B3 cell line, IgG-BF purified from
culture medium of CulB3 (25 Wg),
6/9CII (17 .5 ltg), and IVC2 (25 Wg)
cell lines or from activated T cells (150
ng) by Western blotting with chicken
anti-porcine TGF-(31 (3 Fig/ 1nl) anti-
bodies.
Time of addition (h)
Figure 2 .
￿
Immunosuppressive activities of IgG-BF and ofTGF-R on B cell responses stimulated by anti-IgM . Various doses of IgG-BF (A) or ofpor-
cine TGF-(31 (B) were added on day 0 . Cell proliferation was measured on day 3 by fH]thymidine incorporation. The results are representative of five
experiments . Each bar represents the mean i . SEM ofduplicate samples . In a single kinetic experiment (C), IgG-BF (50 IL ,g/ml) or porcine TGF-(31 (0 .5
ng/ml) was added at various times after the onset ofcultures, and cell proliferation was measured on day 3 . --Q-- , IgG-BF ; --= -, TGF-(3 .0
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cultures. Figs. 2 and 3 illustrate representative results from a
dozen independent experiments using IgG-BF from either
Cu1B3 (two and four experiments performed with anti-
IgM and LPS, respectively) or 6/9CII (three experiments
for each of the two stimuli) cell lines and from four inde-
pendent experiments using porcine TGF-[31 .
Addition of increasing doses of affinity-purified IgG-BF
or porcine TGF-[31 resulted in a dose-dependent inhibi-
tion of B cell proliferation induced by stimulation by anti-
IgM (Fig. 2, A and B) or LPS (Fig. 3, A and B) . In the lat-
ter case, total inhibition of IgM and IgG3 production was
also observed in IgG-BF- and in TGF-(3-treated cultures
(Fig. 3, D and E) . A 50% inhibition ofproliferation and an-
tibody production was achieved by 1 .5 and 5 ~Lg/ml of
IgG-BF, and 0.016 and 0.05 ng/ml ofporcine TGF-[31 in
the LPS- and anti-IgM-stimulated cultures respectively,
which is compatible with the hypothesis that the TGF-P
present in the IgG-BF preparations might be responsible
for suppression. This was reinforced by three independent
kinetic experiments in which porcine TGF-[31, at a dose of
0.05 ng/ml, or IgG-BF, at a dose of 50 N,g/ml, was added
at different times to B cells stimulated by anti-IgM antibod-
ies (Fig. 2 C) or LPS (Fig. 3 C) . These figures illustrate the
result of one of the three experiments performed. Cell pro-
liferation, as assessed by [3H]thymidine incorporation on
day 3 for anti-IgM stimulation or on day 4 for LPS stimula-
tion, was inhibited with the same kinetics by the two prep-
arations, with a maximum when added at the onset of the
cultures, and no significant inhibition when added during
the last 18 h of culture.
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Figure 3 .
￿
Immunosuppressive activities of IgG-BF
and ofTGF-P on B cell responses stimulated by LPS.
Various doses of IgG-BF (A and D) or of porcine
TGF-[31 (B and E) were added on day 0. Cell prolifer-
ation (A and B) was measured on day 4 by [3Hlthymi-
dine incorporation and Ig secretion (IgM, IgG3) (D and
E) by ELISA ofday 7 cell supernatants. Each bar repre-
sents mean ± SEM of duplicate samples. Similar results
were obtained in sevenseparate experiments. In kinetic
experiments (C), IgG-BF (50 lig/ml) or porcine TGF-
01 (0.5 ng/ml) was added at various timesafter the on-
set of cultures, and cell proliferation was measured on
day 4. --a- , IgG-BF; ---*-- , TGF-[3. The results
are representative oftwo independent experiments.
Effect ofAnti-TGF-(3 Antibodies on the Inhibitory Activity of
IgG-BF. To investigate the role ofTGF-P in the suppres-
sive activity exerted by IgG-BF, neutralizing anti-TGF-R
antibodies were added in four repeated independent exper-
iments to cultures of resting B lymphocytes treated with
IgG-BF from the 6/9CII cell line or with porcine TGF-
Rl . As illustrated in Fig. 4, the addition of increasing doses
of chicken anti-porcine TGF-Rl to purified B cells stimu-
lated with anti-IgM antibodies (Fig. 4 A) or with LPS (Fig.
4 B) increased the proliferative response by ^20%, suggest-
ing that TGF-P might be produced during culture and
neutralized by the antibodies cross-reacting with endoge-
nous mouse TGF-(3. Addition of control chicken IgY had
no effect as well as addition of rat anti-mouse FcyR 2.4G2
antibodies (35; data not shown) . The addition of 15 N,g/ml
IgG-BF or 0.1 ng/ml porcine TGF-(31 resulted in -80%
inhibition ofB cell proliferation, which was completely re-
versed, in both cases, by the addition of anti-TGF-[3, but
not by control IgY or 2AG2 antibodies (Fig. 4, A and B;
data not shown) . To ascertain whether the removal of in-
hibitory activity was indeed caused by anti-TGF-[3 anti-
bodies, a mouse mAb was used to neutralize TGF-P activ-
ity. It fully reversed the suppressive activity exerted by
IgG-BF on LPS-induced B cell proliferation, as well as that
of porcine TGF-(31, although less efficiently. An isotype-
matched IgGI had no effect (Fig. 4 Q .
To establish whether TGF-P was also involved in the
suppression exerted by IgG-BF on antibody production to
SR-13C, chicken polyclonal antibodies or mouse mAbs to
TGF-P were added to splenocytes that had been stimulated
A B
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Figure 4. Anti-TGF-(3 neutralized the antiproliferative activities of
IgG-BF and TGF-(3. IgG-BF (50 Ltg/ml), porcine TGF-(31 (1 ng/ml), or
control medium was added on day 0 to anti-IgM- (A) or LPS- (B and C)
stimulated B cell cultures. Various concentrations of chicken polyclonal
anti-porcine TGF-(31 antibodies or control IgY (A and B), and of mouse
monoclonal antibovine TGF-P or control mouse IgG, (C) were added on
day 0 to these cultures. Proliferative responses were measured on day 3
for anti-IgM-stimulated cultures and on day 4 for LPS-stimulated cul-
in vitro with SR-13C in the presence of 15 [tg/ml IgG-BF
or 3 ng/ml TGF-R. We showed in two independent ex-
periments that the inhibitory activity exerted by both fac-
tors on the production ofIgG-PFC was reversed by 45 jig/
ml polyclonal (Fig. 5 A) or 30 uLg/ml monoclonal (Fig. 5
B) anti-TGF-R antibodies, whereas isotype-matched con-
trol Ig had no effect (data not shown). As for mouse B cells,
the addition of anti-TGF-R antibodies increased the num-
ber of PFC by ^20% (Fig, 5, A and B), suggesting that
TGF-P produced during the course of an antigen-stimu-
lated immune reaction modulates the antibody response.
Separation of TGF-,(3 and sFcyR by Gel Exclusion Chroma-
tography. The inhibition of the suppressive activity of IgG-
BF by anti-TGF-R antibodies could be caused by the neu-
tralization of TGF-P present in the IgG-BF preparations or
to TGF-P induced during culture. We therefore attempted
to separate TGF-P from sFcyR before addition to the cul-
tures. This was achieved on a Superdex 75 column (Phar-
macia) . Fig. 6 represents an illustrative experiment, out of
three, in which 91% of TGF-(3, as revealed by Western
blotting, eluted in the void volume, whereas sFcyR, as re-
vealed by ELISA with anti-FcyR antibodies, eluted at Ve/
Vo = 1 .3 (11 .5 ml) . The suppressive activity on B cell pro-
liferation superimposed with the bulk of TGF-R, with no
detectable activity in the fractions containing sFcyR, dem-
onstrating that exogenous TGF-P was responsible for most,
if not all, the inhibition ofB cell responses.
Binding of TGF-P to IgG.
￿
Since TGF-P was present in
IgG-BF isolated by affinity chromatography with insolubi-
lized IgG, binding ofpurified porcine TGF-R1 to IgG was
directly assessed on Sepharose beads coupled with rabbit
IgG or F(ab')2 fragments of rabbit IgG as controls. TGF-P
was detected by Western blotting, ELISA, and by measur-
ing its antiproliferative activity on LPS-stimulated B cell re-
sponses and on secondary anti-SR-BC IgG response. As il-
lustrated in Fig. 7 A, TGF-P was recovered in the acid
eluates of IgG columns, but was barely detectable in those
from F(ab')2 columns. During the course of three indepen-
dent experiments, 28.6 ± 8% of the applied material was
present in the IgG eluates and only 2 ± 1 .3% in the F(ab')2
eluates, as estimated by Western blotting. The results were
confirmed by ELISA (data not shown) . As shown in Fig. 7
B, TGF-P inhibited, in a dose-dependent fashion, the pro-
liferation of mouse resting B cells stimulated by LPS. The
comparison of the antiproliferative activities, in two inde-
pendent experiments, of the various fractions showed that
the eluates from IgG immunoadsorbents and the effluents
from F(ab')2-Sepharose were almost as suppressive as the
starting material, whereas the effluents of the IgG-immu-
noadsorbents and the eluates from F(ab')2-Sepharose were
20-fold less active (Fig. 7 B) . When added to splenocyte
cultures stimulated with SR-13C, TGF-P inhibited IgG an-
tures. Each point represents the mean - SEMofduplicate samples. These
results are representative of four separate experiments. --c- , anti-
TGF/control; - -E~ -, anti-TGF/IgG-BF; ---A7-, anti-TGF/TGF;
--40-- , IgY/control; -N
￿
- , IgY/IgG-BF; --A - , IgY/TGF.
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Anti-TGF-(3 reversed the inhibitory activities of IgG-BF and
TGF-P on secondary anti-SRBC responses in vitro . IgG-BF (5 .5 Fig) or
porcine TGF-(31 (3 ng) was added to anti-SR-BC spleen cell cultures in
the presence or in the absence of chicken polyclonal anti-porcine TGF-
(31 (45 Htg) (A) or mouse monoclonal antibovine TGF-P (30 l ..g) (B) .
Results representative of two independent experiments are expressed as
the number of indirect PFC per 106 recovered cells (means ± SEM of
duplicate values) .
tibody production . The suppressive activity was retained,
and could be eluted from, IgG but not F(ab') Z immunoad-
sorbents (Fig . 7 C) . Overall, these results show that active
TGF-P binds to insolubilized IgG via its Fc portion and
can be eluted from it in an active form .
Discussion
The studies reported here demonstrate that a TGF-{3-like
immunosuppressive factor is responsible for the inhibition
ofB cell proliferation and antibody production exerted by
19G-BF preparations . Several lines of evidence lead to this
conclusion. (a) TGF-P molecules can be detected in IgG-
BF preparations ; (b) not only do TGF-P and IgG-BF in-
hibitB cell proliferation and Ig production in a similar way,
but they do so with identical kinetics ; and (c) the suppres-
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Figure 6 .
￿
Separation of TGF-P from sFcyR by gel exclusion chroma-
tography. (A) OD-280 nm; (B) TGF-P concentration ; (C) sFcyR con-
centration ; (D) antiproliferative activity on LPS-induced B cells (AU, ar-
bitrary units) . Similar results were obtained in three separate experiments .
sive activity exerted by IgG-BF is totally reversed by poly-
clonal and monoclonal antibodies to TGF-(3 .
In mammals, three isoforms of TGF-P share -70-80%
homology and are almost completely conserved between
species (22) . The fact that the suppressive activity of IgG-
BF preparations on LPS- or anti-IgM-stimulated B cells, as
well as on anti-SRBC responses, is inhibited by polyclonal
and monoclonal anti-TGF-R antibodies demonstrates that
TGF-P is involved in the effect, but it does not indicate
which isoform is primarily responsible . The three isoformsFigure 7 .
￿
TGF-P binds to IgG, but not to F(ab')2 fragments . Porcine
TGF-(31 was incubated with IgG or F(ab') 2 immunoadsorbents, Effluents
(EF IgG, EF F(ab') 2) and acid eluates (EL IgG, EL F(ab')2) were recov-
ered . Fractions (30 and 5 ltl) and TGF-R1 (1 and 0.3 ng) were analyzed
by Western blotting with chicken anti-porcine TGF-(31 (A), for biologi-
cal activity on LPS-stimulated proliferative B cell response (B), and on the
secondary in vitro anti-SP-BC response (final dilution = 1 : 200) (G . Re-
sults are expressed as the number of indirect PFC per 106 recovered cells
(means ± SEM of duplicate cultures) .
ofTGF-P bind to the same receptors, although with vari-
able affinities (35), and have similar biological activities .
We did not therefore attempt to characterize the TGF-(3
isoforms present in the IgG-BF preparations . The fact that
neutralizing antibodies reversed suppression suggested either
that TGF-R-like molecules were present in the IgG-BF
preparations, or that the production ofTGF-P was induced
by IgG-BF . Indeed, these antibodies neutralized endoge-
nously produced mouse TGF-P since their addition to ac-
tivated B cells or to SRBC-stimulated splenocyte cultures
enhanced cell responses as already observed (40) . To dis-
criniinate between the two possibilities, it was necessary to
physically separate TGF-P from sFcyR in IgG-BF prepara-
tions . This was achieved on a gel filtration column . When
the different fractions were tested for suppressive activity,
the fractions containing the bulk ofTGF-R were active on
antibody production, in contrast to those containingsFcyR .
Exogenous TGF-P present in IgG-BF preparations seems
therefore responsible for the inhibition ofB cell responses
and antibody production . It is noteworthy that, after gel ex-
clusion chromatography, the bulk ofTGF-P and the sup-
pressive activity were present in the high molecular weight
fractions of the gel exclusion column (>150 kD) . These
results are compatible with the fact that TGF-(3 forms
complexes at neutral pH, as observed by others (26) .
Immunosuppressive factors that bind IgG and not F(ab') 2
have been described by several groups in supernatants of
cells secreting sFcyR such as mouse T cells and T cell lines
and human mononuclear cells or neutrophils (7-14) . They
were isolated using affinity chromatography with insolubi-
lized IgG . The question thus arises whether the results ob-
tained with IgG-BF isolated from cell lines secreting re-
combinant sFcyR can be generalized to the natural factors .
In the present work, Western blotting analysis showed that
25-kD TGF-R was detectable in IgG-BF isolated from su-
pernatants ofmouse activated T cells . It is noteworthy that
suppressive 19-23-kD components have been previously
identified in similar IgG-BF preparations (41) . Compo-
nents migrating above the 25-kD band were detected by
Western blotting in porcine TGF-(3, as well as in T cell-
produced IgG-BF and in IgG-BF purified from the culture
media ofIVC2 and 6/9CII cell lines (Fig . 1 D) . Their iden-
tity is presently unknown . A cross-reactive 35-kD contam-
inant has been already described in human rTGF-(3 (42) .
Finally, our data suggest that the presence ofTGF-P in
IgG-BF preparations is most probably caused by selective
binding ofTGF-P to IgG . Indeed, we demonstrated that
purified porcine TGF-R1 is absorbed on IgG-Sepharose,
and not on F(ab') 2-Sepharose, and recovered in the acid
eluates of IgG-Sepharose . The murine TGF-R-like sup-
pressive factor present in IgG-BF purified from culture me-
dium of the CulB3 cell line also bound to IgG and not to
F(ab')2 fragments of IgG since suppressive activity was eluted
from IgG-Sepharose (Fig . 1 A), and not F(abl-Sepharose
(data not shown), as already observed (19), and TGF-P was
found in the acid eluates from IgG-Sepharose (Fig . 1 Q .
Stach and Rowley (26) recently demonstrated that the
IgG-mediated suppression of in vitro cytotoxic T cell re-
sponses is caused by IgG-bound TGF-(3 . These authors re-
ported that in immune serum, TGF-P circulates with IgG
antibodies at a ratio of 2-10 ng TGF-P for 1 mg IgG.
TGF-(3-induced T cell suppression was inhibited by anti-
TGF-(3 antibodies, but also by rabbit IgG and anti-FcyR
antibodies, and it required interaction with macrophage
FcyR (26) . Our own data emphasize the role of TGF-P
and its binding to IgG in the modulation of B cell re-
sponses .
TGF-P is synthesized bymany cell types and secreted al-
most exclusively as a biologically inactive or "latent" com-
plex (30, 43) that can be activated by exposure to acidic or
alkaline environments, by heating at 100°C, by treatment
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teases and glycosidases (29, 44). TGF-(3, recovered in the
acid eluates of IgG-Sepharose, was suppressive for B cell
proliferation and antibody production and its effect was in-
hibited by antibodies reacting with active TGF-(3, suggest-
ing that TGF-P was present in an active form. It is unclear
whether it was already active in the starting culture me-
dium. Many studies have shown that latent TGF-P must be
acidified to <pH 4 to obtain efficient activation (44) . In
this study, all purification steps ofrecombinant sFcyRwere
performed >pH 4. The culture medium of Cu1B3 cell line
grown on hollow fibers was suppressive (Fig. 1 A) and con-
tained TGF-R, as demonstrated by Western blotting (Fig. 1
D) . Similar results were obtained with the culture media of
6/9CII and IVC2 cell lines (data not shown). It is possible
that the culture of transfected cells in bioreactors at high
cell density for several weeks may lead to a certain degree
of cell death and to the release of proteases, resulting in ac-
tivation of latent TGF-R . The fact that the crude culture
medium of the 6/9CII cell line grown in bioreactors inhib-
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